![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
Tesla
TSLA
NVIDIA
NVDA
Palantir
PLTR
4
Apple
AAPL
5
Advanced Micro Devices
AMD
US Stock MarketDetailed Quotes
CTXR Citius Pharmaceuticals
- 1.5800
- 0.00000.00%
Trading Mar 11 11:53 ET
13.58MMarket Cap-0.27P/E (TTM)
1.5800High1.5500Low22.26KVolume1.5500Open1.5800Pre Close34.72KTurnover0.28%Turnover RatioLossP/E (Static)8.59MShares26.750052wk High0.21P/B12.39MFloat Cap1.470052wk Low--Dividend TTM7.84MShs Float750.0000Historical High--Div YieldTTM1.90%Amplitude1.4700Historical Low1.5590Avg Price1Lot Size
Citius Pharmaceuticals Stock Forum
Sign in to post a comment
$Citius Pharmaceuticals (CTXR.US)$
Citius Pharmaceuticals Secures Critical J-Code for LYMPHIR as Cash Reserves Hit $1.1M
Citius Pharmaceuticals Secures Critical J-Code for LYMPHIR as Cash Reserves Hit $1.1M
1
2
$Citius Pharmaceuticals (CTXR.US)$
Medicare Breakthrough: Citius's Cancer Drug LYMPHIR Gets Crucial Insurance Code - Major Win for CTCL Patients
Medicare Breakthrough: Citius's Cancer Drug LYMPHIR Gets Crucial Insurance Code - Major Win for CTCL Patients
1
$Citius Pharmaceuticals (CTXR.US)$ $Citius Oncology (CTOR.US)$ Reuters· just
Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for Lymphir by Centers for Medicare and Medicaid Services
Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for Lymphir by Centers for Medicare and Medicaid Services
5
$Citius Pharmaceuticals (CTXR.US)$
Citius Pharmaceuticals Advances LYMPHIR Launch Plans for Breakthrough CTCL Treatment
Citius Pharmaceuticals Advances LYMPHIR Launch Plans for Breakthrough CTCL Treatment
3
$Citius Pharmaceuticals (CTXR.US)$ $Citius Oncology (CTOR.US)$ Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025
PR Newswire· 4 mins ago
PR Newswire· 4 mins ago
2
$Citius Pharmaceuticals (CTXR.US)$ $Citius Oncology (CTOR.US)$
Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025
Tuesday, 7th January at 8:08 am
CRANFORD, N.J., Jan. 7, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (NASDAQ: CTXR) and its oncology-focused subsidiary, Citius Oncology (NASDAQ: CTOR), today announced significant progress in preparations for the commercial launch of LYMPHIR™, an i...
Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025
Tuesday, 7th January at 8:08 am
CRANFORD, N.J., Jan. 7, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (NASDAQ: CTXR) and its oncology-focused subsidiary, Citius Oncology (NASDAQ: CTOR), today announced significant progress in preparations for the commercial launch of LYMPHIR™, an i...
$Citius Pharmaceuticals (CTXR.US)$
The engagement of Jefferies as a financial advisor is a strategically significant move that could reshape Citius Oncology's future. Jefferies' strong track record in healthcare M&A and their expertise in orchestrating deals averaging $500M-$2B in the biotech sector positions them well to explore value-maximizing opportunities. With LYMPHIR™ recently FDA-approved and ready for commercialization, the timing aligns perfectly with...
The engagement of Jefferies as a financial advisor is a strategically significant move that could reshape Citius Oncology's future. Jefferies' strong track record in healthcare M&A and their expertise in orchestrating deals averaging $500M-$2B in the biotech sector positions them well to explore value-maximizing opportunities. With LYMPHIR™ recently FDA-approved and ready for commercialization, the timing aligns perfectly with...
6
$Citius Pharmaceuticals (CTXR.US)$
Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives
Monday, 6th January at 7:50 am
CRANFORD, N.J., Jan. 6, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or "the Company") (NASDAQ: CTOR), a majority-owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (NASDAQ: CTXR), today announced that it has retained Jefferies LLC as its exclusive financial advisor to assist in evaluating strategi...
Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives
Monday, 6th January at 7:50 am
CRANFORD, N.J., Jan. 6, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or "the Company") (NASDAQ: CTOR), a majority-owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (NASDAQ: CTXR), today announced that it has retained Jefferies LLC as its exclusive financial advisor to assist in evaluating strategi...
18
11
No comment yet
萬軍無兵策天鳳 : Summary: There is no hope left.![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
71079745 萬軍無兵策天鳳 : There is hope, there is hope, do not be too pessimistic, we simply won't buy it.